---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-019370"
form_type: "8-K"
ticker: "BFRI"
cik: "0001858685"
company_name: "Biofrontera Inc."
filed_at: "2025-10-24T23:59:59+00:00"
generated_at: "2026-05-17T02:22:07.518241+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Biofrontera closes acquisition of U.S. rights to Ameluz; raises $2.5M in Series C preferred

## Summary
- Acquired all U.S. rights to Ameluz and RhodoLED from former parent Biofrontera AG per Asset Purchase Agreement dated Oct 20, 2025.
- Earnout replaces prior transfer pricing model: 12% of U.S. net sales ≤$65M, 15% if >$65M.
- Closed second tranche of Series C Preferred Stock, raising $2.5M gross; total offering now $11M.
- Believes stockholders' equity now exceeds $5M, regaining compliance with Nasdaq minimum equity requirement.
- Proceeds from preferred stock to fund acquisition and transfer costs and general corporate purposes.

## SEC filing metadata
- accession: 0001493152-25-019370
- form_type: 8-K
- ticker: BFRI
- cik: 0001858685
- company_name: Biofrontera Inc.
- filed_at: 2025-10-24T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 3.02, 8.01, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1858685/000149315225019370/0001493152-25-019370-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1858685/000149315225019370/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-019370
- JSON: https://secwatch.observer/filing/0001493152-25-019370.json
- Plain text: https://secwatch.observer/filing/0001493152-25-019370.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.